Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sipuleucel-T - Dendreon Corporation

Next Previous
Drug Profile

Sipuleucel-T - Dendreon Corporation

Alternative Names: APC-8015; APC8015F; Autologous PAP-loaded dendritic cell vaccine - Dendreon; Prostate cancer vaccine (APC-8015) - Dendreon; Prostate-cancer-vaccine-APC-8015-Dendreon; Provenge

Latest Information Update: 22 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dendreon Corporation
  • Class Antineoplastics; Cancer vaccines; Dendritic cell vaccines; Immunotherapies; T lymphocyte cell therapies; Tissue extracts
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Prostate cancer

Most Recent Events

  • 22 Nov 2023 Dendreon plans the phase III ProvONE trial in Prostate cancer (Metastatic disease) (IV) in November 2023 (NCT06134232)
  • 10 Mar 2023 Dendreon Pharmaceuticals completes a phase III ProVent trial for Prostate cancer in USA (IV, Infusion) (NCT03686683)
  • 31 Dec 2020 University of Hawaii, Genentech and Dendreon completed the phase Ib trial for Prostate cancer (Hormone refractory, Metastatic disease) in USA (IV) (NCT03024216)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top